Clinical and molecular aspects of breast cancer: Targets and therapies

R L N Godone; G M Leitão; N B Araújo; C H M Castelletti; J L Lima-Filho; D B G Martins

doi:10.1016/j.biopha.2018.06.066

Clinical and molecular aspects of breast cancer: Targets and therapies

Biomed Pharmacother. 2018 Oct:106:14-34. doi: 10.1016/j.biopha.2018.06.066. Epub 2018 Jun 23.

Authors

R L N Godone¹, G M Leitão², N B Araújo¹, C H M Castelletti³, J L Lima-Filho⁴, D B G Martins⁵

Affiliations

¹ Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil.
² Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil; Clinical Hospital of Pernambuco - Professor Romero Marques, Federal University of Pernambuco (UFPE), Brazil.
³ Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil; Agronomic Institute of Pernambuco (IPA), Recife, Pernambuco, Brazil.
⁴ Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil; Department of Biochemistry, Federal University of Pernambuco (UFPE), Brazil.
⁵ Molecular Prospection and Bioinformatics Group, Laboratory Keizo Asami of Immunopathology (LIKA), Federal University of Pernambuco (UFPE), Brazil; Department of Biochemistry, Federal University of Pernambuco (UFPE), Brazil. Electronic address: bruneska@prospecmol.org.

PMID: 29945114
DOI: 10.1016/j.biopha.2018.06.066

Abstract

Breast Cancer is a complex disease characterized by the occurrence of multiple molecular alterations. Currently, some molecular markers are in use for breast cancer diagnostic, prognostic, and predictive purposes. Thus, genetic signatures are available for improving the decision-making. The biomarkers are also essential as therapeutic approaches, but many questions remain due to the lack of efficacy on breast cancer treatment, mainly for triple-negative breast cancer subtype. Since the genetic profile of breast cancer can also be related to different ethnic groups and geographic areas, the reference populations of the genetic assays and clinical trials need to include a broader population beyond the European and North American patients. In this review, we analyzed the current and potential molecular markers that could help to improve the strategies for breast cancer therapy.

Keywords: Biological markers; Breast cancer; Molecular targeted therapy.

Publication types

Review

MeSH terms

Antineoplastic Agents / therapeutic use*
Biomarkers, Tumor / antagonists & inhibitors*
Biomarkers, Tumor / genetics
Biomarkers, Tumor / metabolism
Breast Neoplasms / drug therapy*
Breast Neoplasms / ethnology
Breast Neoplasms / genetics
Breast Neoplasms / metabolism
Clinical Decision-Making
Female
Gene Expression Profiling
Humans
Molecular Targeted Therapy*
Patient Selection
Precision Medicine
Predictive Value of Tests
Signal Transduction / drug effects
Transcriptome

Substances

Antineoplastic Agents
Biomarkers, Tumor